Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection

被引:15
作者
Pelak, BA
Citron, DM
Motyl, M
Goldstein, EJC
Woods, GL
Teppler, H
机构
[1] Merck Res Labs, Rahway, NJ USA
[2] RM Alden Res Lab, Santa Monica, CA USA
[3] Merck Res Labs, W Point, PA 19486 USA
关键词
D O I
10.1093/jac/dkf203
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study compared the in vitro activities of ertapenem, ceftriaxone, co-amoxiclav, ciprofloxacin and piperacillin-tazobactam against 314 aerobic bacteria and of ertapenem, piperacillin-tazobactam, cefoxitin, ceftriaxone, chloramphenicol, ticarcillin-clavulanate, ampicillin-sulbactam, clindamycin and metronidazole against 500 anaerobic bacteria from 212 patients with acute pelvic infection. Antimicrobial susceptibilities were determined by broth microdilution (aerobes) or agar dilution (anaerobes), following NCCLS guidelines. The most common isolates were Enterobacteriaceae and Peptostreptococcus spp. Ertapenem was the most active drug tested against Enterobacteriaceae (100% susceptible) and anaerobes (99.8% susceptible); the least active agents were co-amoxiclav (79% of Enterobacteriaceae susceptible) and ceftriaxone (85.9% of anaerobes susceptible). All agents tested had excellent activity against beta-haemolytic streptococci and methicillin-susceptible Staphylococcus aureus.
引用
收藏
页码:735 / 741
页数:7
相关论文
共 11 条
  • [1] APUZZIO JJ, 1989, AM J MED S5A, V87, P148
  • [2] AMPICILLIN SULBACTAM VERSUS METRONIDAZOLE-GENTAMICIN IN THE TREATMENT OF SOFT-TISSUE PELVIC INFECTIONS
    CROMBLEHOLME, WR
    OHMSMITH, M
    ROBBIE, MO
    DEKAY, V
    SWEET, RL
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1987, 156 (02) : 507 - 512
  • [3] In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers
    Fuchs, PC
    Barry, AL
    Brown, SD
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) : 1915 - 1918
  • [4] GALL S, 1990, J REPROD MED, V35, P1091
  • [5] In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia
    Livermore, DM
    Carter, MW
    Bagel, S
    Wiedemann, B
    Baquero, F
    Loza, E
    Endtz, HP
    van den Braak, N
    Fernandes, CJ
    Fernandes, L
    Frimodt-Moller, N
    Rasmussen, LS
    Giamarellou, H
    Giamarellos-Bourboulis, E
    Jarlier, V
    Nguyen, J
    Nord, CE
    Struelens, MJ
    Nonhoff, C
    Turnidge, J
    Bell, J
    Zbinden, R
    Pfister, S
    Mixson, L
    Shungu, DL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) : 1860 - 1867
  • [6] Murray P.R., 1999, MANUAL CLIN MICROBIO, V7th
  • [7] *NAT COMM CLIN LAB, 2001, M11A5 NCCLS
  • [8] National Committee for Clinical Laboratory Standards, 2000, M7A5 NCCLS
  • [9] ROY S, 2001, 41 INT C ANT AG CHEM, P456
  • [10] Summanen P, 1993, WADSWORTH ANAEROBIC